Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
5',3'-Nucleotidase, cytosolic pseudogene 2 (NT5CP2) is classified as a pseudogene, which means it is a non-functional gene sequence that is related to protein-coding 5'-nucleotidase family genes, but does not produce a functional protein product or have a known biological role[1]. Unlike NT5C3 or NT5C2, which encode active enzymes involved in nucleotide metabolism and are studied in disease, NT5CP2 is annotated as a pseudogene without evidence of therapeutic relevance or druggability[1][2]. Thus, NT5CP2 is not a recognized receptor, enzyme, transporter, or other common therapeutic target. There is nothing to support NT5CP2 as a functional, druggable, or disease-associated molecule; any association with therapy, mechanism, or biomarker status is not currently recognized in major scientific resources[1][2]. The main error is that NT5CP2 itself is a pseudogene and not a protein-coding target. If you intended to ask about Cytosolic 5'-nucleotidase 3 (NT5C3), which is a functional enzyme and a drug metabolism target, please clarify, as that is a distinct, biologically active protein[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 5',3'-Nucleotidase, cytosolic pseudogene 2 (NT5CP2).